Drug Trial Radar · NCT05721300
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,215
Planned (sponsor's estimate)
Start
Feb 10, 2023
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are: 1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment; 2. Repetitive effect and time effect of different drug treatment at different follow-up time points; 3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon; 4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination. Researchers will compare control group to see if occurrence of liver cancer.
Conditions
- Hepatocellular Carcinoma
- Chronic Hepatitis B
Interventions
NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined with interferon treatmentsDrug
NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combine with interferon treatments for 48 weeks, and then continue with NAs treatment("Entecavir"or"Tenofovir"or"Tenofovir alafenamide")
NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatmentsDrug
patients receive NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatment at least 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of early liver cancerTime frame: 1-3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boheng Zhang
Xiamen, Fujian, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.